Pharmala Biotech Shares Surge 9.38 % in a Single Day

Pharmala Biotech (MDMA.CN) experienced a notable rally, climbing 9.38 % during a 24‑hour trading window that concluded at 10:44 PM Central Europe on Wednesday, 21 st. At the time of writing, one share is available on major exchanges for approximately CAD 0.17. The company’s outstanding share base stands at 109.7 million, yielding a market capitalisation of CAD 17.6 million. Over the past 24 hours, the total volume traded has approached CAD 16.4 k.

Despite the recent uptick, Pharmala’s stock has seen a significant decline since the previous month’s end, falling 32.69 %. Technical indicators place the 200‑day simple moving average at CAD 0.15. The highest price recorded in the past 52 weeks was CAD 0.33 on 9 October 2026, while the 52‑week low fell to CAD 0.08 on 9 April 2026.

Context from Peer Performance

The broader sector has shown mixed momentum:

  • Verdera Energy (V.V) – Down 6.9 %, now at CAD 0.28, with a market cap of CAD 20.8 million.
  • Dr Phone Fix Canada (DPF.V) – Down 4.35 %, now at CAD 0.11, market cap of CAD 21 million.
  • Aegis Brands (AEG.TO) – Down 2 %, now at CAD 0.24, market cap of CAD 20.9 million; price‑earnings ratio of 5.7.
  • Au Gold (AUGC.V) – Down 1.75 %, now at CAD 0.28, market cap of CAD 21 million.
  • Manganese X Energy (MN.V) – Flat, trading at CAD 0.09, market cap of CAD 20.7 million.

The relative strength of Pharmala’s rally suggests investor confidence in its strategic positioning within the oncology niche, even as the broader market shows a range of performance outcomes.

Company Overview

Pharmala Biotech Holdings Inc. is a Canadian biotechnology enterprise focused on developing and commercialising novel therapeutic agents for a variety of diseases, with a primary emphasis on oncology. The firm has cultivated a robust reputation for its innovative drug‑discovery methodologies and maintains a portfolio of proprietary technologies and intellectual property rights in cancer biology. Pharmala’s mission is to transform patient outcomes by delivering breakthrough therapies that address unmet medical needs.

Operating through two principal divisions—Research and Development, and Commercialisation—Pharmala is committed to sustainable growth. The company actively pursues long‑term partnerships with other biotechnology firms, academic researchers, and stakeholders throughout the healthcare ecosystem, aiming to accelerate the translation of scientific discoveries into clinical applications.

This article synthesises publicly available market data and corporate information to provide an informed snapshot of Pharmala Biotech’s recent trading activity and strategic context.